effects: risk of worsening of myasthenia gravis (muscle weakness), loss of consciousness, visual disturbances, heart rhythm disorders, and liver damage.
Status: Withdrawn from the market in Europe (including France) in January 2018 by decision of the laboratory, following serious risks (hepatic, cardiac, neurological) and a decrease in prescriptions; stocks exhausted in 2019.
– NEXEN
Indications: osteoarthritis and painful periods.
Side effects: liver disorders, sometimes fatal, fulminant hepatitis.
Status: Restricted in France since June 2012 (European reassessment initiated in 2010), limited to acute pain and primary dysmenorrhea for short duration (15 days